Zevra Therapeutics names interim principal financial officer

Zevra Therapeutics, Inc. reported a leadership change in its finance organization.

Accepted by SEC EDGAR 12/17/2025 - 04:15 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Zevra Therapeutics, Inc. reported a leadership change in its finance organization. The board appointed Timothy Sangiovanni, currently Senior Vice President, Finance and Corporate Controller and principal accounting officer, to serve as interim principal financial officer effective January 1, 2026. He has held senior finance and reporting roles at the company since 2015. The company noted that there was no change to Mr. Sangiovanni’s compensation arrangements in connection with this interim appointment.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Zevra Therapeutics (ZVRA) disclose in this 8-K filing?

The company disclosed that its board appointed Timothy Sangiovanni as interim principal financial officer, effective January 1, 2026.

Who is Timothy Sangiovanni at Zevra Therapeutics (ZVRA)?

Timothy Sangiovanni is the company’s Senior Vice President, Finance and Corporate Controller and principal accounting officer, and will also serve as interim principal financial officer.

When does the new interim principal financial officer role become effective at Zevra Therapeutics?

Mr. Sangiovanni’s appointment as interim principal financial officer becomes effective on January 1, 2026.

Did Zevra Therapeutics change Timothy Sangiovanni’s compensation with this appointment?

No. The company stated there was no change to Mr. Sangiovanni’s compensation arrangements in connection with his appointment as interim principal financial officer.

What experience does Timothy Sangiovanni have at Zevra Therapeutics?

He has served as Senior Vice President, Finance and Corporate Controller since January 2023, previously as Vice President, Corporate Controller from February 2017 to January 2023, and as Director of Financial Reporting from August 2015 to February 2017.

What exhibit was included with Zevra Therapeutics’ 8-K filing?

The filing included exhibit 104, a Cover Page Interactive Data File embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000143464700014346472025-12-112025-12-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________________________________________________________

FORM 8-K

__________________________________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 11, 2025

__________________________________________________________________________________________ 

Zevra Therapeutics, Inc

(Exact Name of Registrant as Specified in Its Charter)

__________________________________________________________________________________________

Delaware			001-36913			20-5894398
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
1180 Celebration Boulevard, Suite 103, Celebration, FL						34747
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (321) 939-3416

(Former Name or Former Address, if Changed Since Last Report)

__________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001 per share			ZVRA			The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c) On December 11, 2025, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Timothy Sangiovanni, the Company’s current Senior Vice President, Finance and Corporate Controller and principal accounting officer, as interim principal financial officer, effective as of January 1, 2026. Mr. Sangiovanni has served as Senior Vice President, Finance and Corporate Controller of the Company since January 2023. Prior to that, he served as Vice President, Corporate Controller from February 2017 to January 2023 and Director of Financial Reporting from August 2015 to February 2017. There was no change to Mr. Sangiovanni’s compensation arrangements in connection with his appointment as interim principal financial officer.

Item 9.01          Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

 SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						Zevra Therapeutics, Inc.
Date: December 17, 2025						By:			/s/ Timothy J. Sangiovanni
									Timothy J. Sangiovanni, CPA
									Senior Vice President, Finance and Corporate Controller